KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Short-Term Debt issuances (2020)

TherapeuticsMD (TXMD) has disclosed Short-Term Debt issuances for 4 consecutive years, with $50.0 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Short-Term Debt issuances changed N/A year-over-year to $50.0 million, compared with a TTM value of $50.0 million through Dec 2020, changed N/A, and an annual FY2020 reading of $50.0 million, down 75.0% over the prior year.
  • Short-Term Debt issuances was $50.0 million for Q1 2020 at TherapeuticsMD, up from $400000.0 in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $50.0 million in Q1 2020 and bottomed at $50.0 million in Q1 2020.